TY - JOUR
T1 - Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
AU - Ni, Shuaijian
AU - Zhuo, Zhenjian
AU - Pan, Yufei
AU - Yu, Yuanyuan
AU - Li, Fangfei
AU - Liu, Jin
AU - Wang, Luyao
AU - Wu, Xiaoqiu
AU - Li, Dijie
AU - Wan, Youyang
AU - Zhang, Lihe
AU - Yang, Zhenjun
AU - Zhang, Bao-Ting
AU - Lu, Aiping
AU - Zhang, Ge
N1 - Funding Information:
This study was supported by the National Key R&D Program of China (2018YFA0800804), Hong Kong General Research Fund (HKBU 12114416, HKBU 12101117, HKBU 12100918, HKBU 12101018, HKBU 12103519, HKBU 14100218), Direct Grant of The Chinese University of Hong Kong (2018.094), Interdisciplinary Research Clusters Matching Scheme of Hong Kong Baptist University (RC-IRCs/17-18/02), Science and Technology Innovation Commission of Shenzhen Municipality Funds (JCYJ20160229210357960), and Dr. Kennedy Y. H. Wong Distinguished Visiting Professorship Scheme 2018/19, Hong Kong Baptist University.
Publisher copyright:
© 2020 American Chemical Society. All rights reserved.
PY - 2021/3/3
Y1 - 2021/3/3
N2 - Aptamers are oligonucleotide sequences with a length of about 25-80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer-drug conjugates, and targeted delivery materials are comprehensively summarized.
AB - Aptamers are oligonucleotide sequences with a length of about 25-80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer-drug conjugates, and targeted delivery materials are comprehensively summarized.
KW - aptamer
KW - aptamer-drug conjugate (ApDC)
KW - long-acting modification
KW - microfluidic SELEX
KW - nanoparticle
KW - targeted delivery materials
KW - therapeutic application
UR - http://www.scopus.com/inward/record.url?scp=85087676939&partnerID=8YFLogxK
U2 - 10.1021/acsami.0c05750
DO - 10.1021/acsami.0c05750
M3 - Journal article
C2 - 32603135
AN - SCOPUS:85087676939
SN - 1944-8244
VL - 13
SP - 9500
EP - 9519
JO - ACS Applied Materials and Interfaces
JF - ACS Applied Materials and Interfaces
IS - 8
ER -